Abstract
Over the past decade different effective treatment options for use in pulmonary arterial hypertension (PAH) have been developed. Due to multiple pathophysiological pathways in PAH and unsatisfactory overall results with the use of monotherapy in a substantial number of PAH patients, there is a pharmacological rationale for combination therapy. The currently approved substances target the prostacyclin, the endothelin and the NO (nitric oxide) -pathways. Those agents have shown a varying degree of improvement in different categories of PAH associated limitations like hemodynamics, exercise capacity, functional class, and quality of life. However, clinical worsening over time is still significant in most patients irrespective of the treatment utilized. The recently published ESC-ERS (European Society of Cardiology and European Respiratory Society) guidelines on pulmonary hypertension suggest the use of combination therapy in patients who do not respond adequately to monotheapy. This article reviews and critically discusses the available data on combination therapy in PAH.
Keywords: Combination therapy, endothelin receptor antagonists, phosphodiesterase-5-inhibitors, prostanoids, pulmonary hypertension, randomized controlled trials, open-label, nitric oxide, epoprostenol
Current Vascular Pharmacology
Title: Pulmonary Hypertension: Role of Combination Therapy
Volume: 9 Issue: 4
Author(s): Tobias Meis and Juergen Behr
Affiliation:
Keywords: Combination therapy, endothelin receptor antagonists, phosphodiesterase-5-inhibitors, prostanoids, pulmonary hypertension, randomized controlled trials, open-label, nitric oxide, epoprostenol
Abstract: Over the past decade different effective treatment options for use in pulmonary arterial hypertension (PAH) have been developed. Due to multiple pathophysiological pathways in PAH and unsatisfactory overall results with the use of monotherapy in a substantial number of PAH patients, there is a pharmacological rationale for combination therapy. The currently approved substances target the prostacyclin, the endothelin and the NO (nitric oxide) -pathways. Those agents have shown a varying degree of improvement in different categories of PAH associated limitations like hemodynamics, exercise capacity, functional class, and quality of life. However, clinical worsening over time is still significant in most patients irrespective of the treatment utilized. The recently published ESC-ERS (European Society of Cardiology and European Respiratory Society) guidelines on pulmonary hypertension suggest the use of combination therapy in patients who do not respond adequately to monotheapy. This article reviews and critically discusses the available data on combination therapy in PAH.
Export Options
About this article
Cite this article as:
Meis Tobias and Behr Juergen, Pulmonary Hypertension: Role of Combination Therapy, Current Vascular Pharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157016111796197242
DOI https://dx.doi.org/10.2174/157016111796197242 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
EDITORIAL [Hot Topic: Novel Therapeutic Targets of the Renin-Angiotensin System (Guest Editor: Rajesh Kumar)]
Current Hypertension Reviews Chemistry-based Design of Inhibitors for Carboxypeptidase A
Current Topics in Medicinal Chemistry Monocytes and Macrophages as Cellular Targets in Liver Fibrosis
Inflammation & Allergy - Drug Targets (Discontinued) Role of Renin-Angiotensin System in Vascular Endothelial Dysfunction of Pregnancy-Induced Hypertension
Current Hypertension Reviews Hibiscus Sabdariffa Linnaeus (Malvaceae), Curcumin and Resveratrol as Alternative Medicinal Agents Against Metabolic Syndrome
Cardiovascular & Hematological Agents in Medicinal Chemistry Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Mechanisms, Prevention and Treatment of Distal Embolization
Current Pharmaceutical Design Sodium Intake Recommendations: A Subject that Needs to be Reconsidered
Current Hypertension Reviews The Assessment of Interleukin-18 on the Risk of Coronary Heart Disease
Medicinal Chemistry Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Synthesis of Novel 3(N,N-dialkylamino)alkyl/phenyl Substituted Thieno [2,3-d]pyrimidinones as H1-Anti-Histaminic and Antimicrobial Agents
Current Bioactive Compounds Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization
Current Protein & Peptide Science Hypoxic Pulmonary Hypertension, Novel Predisposing Factors, Unsuspected Mechanisms
Current Respiratory Medicine Reviews Recent Patents on Oral Combination Drug Delivery and Formulations
Recent Patents on Drug Delivery & Formulation Editorial: [Hot Topic: Nanotechnology and Patents in Agriculture, Food Technology, Nutrition and Medicine - Advantages and Risks]
Recent Patents on Food, Nutrition & Agriculture Genetic Lipodystrophies: Models for Insulin Resistance
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Assessment of Prescription Pattern in Asthma Therapy at Shamli Hospitals
Reviews on Recent Clinical Trials Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Current Pharmaceutical Design